Every 10-Q that KRAIG BIOCRAFT LABS INC (KBLB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KBLB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KBLB filings page.
Kraig Biocraft Laboratories, Inc. reported no revenue for the three and six months ended June 30, 2026 and remains a development-stage company focused on recombinant spider silk fibers. The company posted a net loss of $909,535 for the quarter and $1,852,255 for the six months, compared with losses of $726,133 and $1,326,166 in the prior-year periods.
Cash and cash equivalents increased to $3,391,646 from $1,790,236 at December 31, 2025, primarily from raising $2,772,547 via a Standby Equity Purchase Agreement. Operating cash used was $1,128,413 for the six months. The balance sheet shows total assets of $4,271,792 and a stockholders’ deficit of $(6,751,116), improved from $(7,998,958) at year-end, but the company still has a working capital deficiency of $7,326,899.
Management explicitly states that these deficits and continued cash burn raise substantial doubt about the ability to continue as a going concern. The company carries a related-party note payable of $1,492,000 and related-party accounts payable and accrued expenses of $8,767,002, including accrued CEO salary and interest. Kraig also holds $440,652 in gold bullion and $3,281,516 in a government money market fund at fair value, and has expanded leasing and production commitments in Vietnam through multiple long-term operating leases.
Kraig Biocraft Laboratories reported first‑quarter 2026 results with no revenue and a net loss of $942,720, wider than the prior‑year quarter. Operating expenses reached $825,500, driven by general and administrative costs, officer salary, professional fees and higher research and development spending.
Cash and cash equivalents increased to $2,890,990 as of March 31, 2026, mainly from $1,644,588 raised under a Standby Equity Purchase Agreement, for which 16,581,603 new shares were issued. Despite the stronger cash balance, the company had a working capital deficiency of $7,666,616, a stockholders’ deficit of $7,061,674 and total liabilities of $10,783,506 against assets of $3,721,832. Management disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
Kraig Biocraft Laboratories (KBLB) reported Q3 results with revenue of $0 and a net loss of $1,509,566 for the quarter; the nine‑month net loss was $2,835,732. Operating expenses were $1,433,888 in Q3 and $2,652,125 year‑to‑date.
As of September 30, 2025, the Company had cash of $1,565,692, a working capital deficiency of $8,544,784, and a stockholders’ deficit of $7,956,077. Management disclosed that these conditions raise substantial doubt about the Company’s ability to continue as a going concern.
Financing activity included $1,925,702 raised under a Standby Equity Purchase Agreement and common shares issued for services valued at $834,600. The Company sold 111 ounces of gold year‑to‑date for $369,992 in proceeds, recognizing a $160,896 realized gain; remaining gold was carried at $494,478. Related‑party note payable was $1,567,000 with $426,589 in year‑to‑date interest expense. Accounts payable and accrued expenses – related party were $8,004,099. Class A shares outstanding were 1,080,852,130 as of November 12, 2025; 1,076,244,777 were outstanding as of September 30, 2025.